tbuckley/cabot-search huggingface dataset:
502P Association of immunotherapy and immunosuppression with severe COVID-19 disease in patients with cancer
Authors: Z. Bakouny, P. Grover, C. Labaki, J. Awosika, S. Gulati, C-Y. Hsu, M.A. Bilen, O. Eton, L. Fecher, C. Hwang, H. Khan, R.R. McKay, E. Ruiz, L. Weissmann, M.A. Thompson, D. Shah, J. Warner, Y. Shyr, T.K. Choueiri, T. Wise-Draper
Journal: Annals of Oncology (2022)
908P Evaluation of anxiety, distress and satisfaction with a multi-cancer early detection test
Authors: D. Schrag, T.M. Beer, C.H. McDonnell, L. Nadauld, C.A. Dilaveri, E.A. Klein, R. Reid, C.R. Marinac, K.C. Chung, M. Lopatin, E.T. Fung, D.L. Patrick
Journal: Annals of Oncology (2022)
285MO The combination of lomustine and antibody-based targeted TNF (L19TNF) as a promising treatment for recurrent glioblastoma
Authors: T. Weiss, T. Look, E. Puca, T. Hemmerle, R. De Luca, R. Stucchi, P. Roth, D. Neri, M. Weller
Journal: Annals of Oncology (2022)
350P Postoperative histopathological, clinical and molecular risk score for patients with colorectal liver metastases
Authors: B. Martin Cullell, A.C. Virgili Manrique, P. Riera, C. Fumagalli, A. Sebio Garcia, O. Mirallas, F. Pelegrin, S. Sánchez-Cabús, V. Molina, A. Gonzalez, J. Szafranska, D. Paez
Journal: Annals of Oncology (2022)
652O Randomized phase III VANCE study: Gemcitabine and carboplatin (GC) followed by Epstein Barr virus-specific autologous cytotoxic T lymphocytes (EBV-CTL) versus the same chemotherapy as first-line treatment for advanced nasopharyngeal carcinoma (NPC)
Authors: H.C. Toh, M-H. Yang, H-M. Wang, C-Y. Hsieh, I. Chitapanarux, K.F. Ho, R-L. Hong, M-K. Ang, D. Colevas, E. Sirachainan, C. Lertbutsayanukul, G.F. Ho, J. Samol, Z. Huang, C. Tan, C. Ding, A. Myo
Journal: Annals of Oncology (2022)
227P Peripheral blood lymphocyte counts predict clinical outcomes in patients with hormone receptor-positive HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
Authors: C. Vernieri, E. Zattarin, L. Mariani, A. Menichetti, R. Leporati, F. Ligorio, G. Fuca, R. Lobefaro, G. Griguolo, M. Sirico, O. Bernocchi, A. Marra, E. Agostinetto, F. Jacobs, P. di Mauro, G. Curigliano, R. Pedersini, A. Losurdo, D. Generali, M.V. Dieci
Journal: Annals of Oncology (2022)
537P A phase I/II study of oral chk1 inhibitor LY2880070 in combination with low-dose gemcitabine in patients with advanced or metastatic ovarian cancer
Authors: W.H. Miller, A.F. Shields, D. Provencher, L. Gilbert, G. Shapiro, A.M. Oza, J. Spratlin, S. Lheureux, G. Bhat, S. Salvador, P. Nunes, S. Lau, I. Weiner, J. Keene, S. Zaknoen, P. Smith, J. Stille, D. Vincett, Q.S-C. Chu
Journal: Annals of Oncology (2022)
682P Patient characteristics and treatment patterns of newly diagnosed locally advanced head and neck squamous cell carcinoma (LA HNSCC): A retrospective cohort analysis of real-world data in England
Authors: A. Kong, G. Chiu, S.R. Shah, J. Bolodeoku, C.S. Casey, O. Massey, A. Patel, C.M. Black
Journal: Annals of Oncology (2022)
543P Can we predict the long and short-term survivors with advanced ovarian cancer?
Authors: E. Shachar, Y. Raz, S. Peleg Hasson, B. Levy, L. Adar, Z.G. Honig, N. Mischan, I. Laskov, D. Grisaru, I. Wolf, T. Safra
Journal: Annals of Oncology (2022)
426P Assessing nivolumab in class II expressing microsatellite stable (pMMR) colorectal cancer (CRC): Results of the ANICCA-Class II trial
Authors: G. Middleton, W. Liu, J. Savage, J.A. Bridgewater, P. Ross, M.P. Saunders, R. Plummer, S. Clive, V. Coyle, A. Thomas, None P. Taniere, L. Billingham
Journal: Annals of Oncology (2022)
686P Next generation sequencing (NGS) helps predict response to immunotherapy (IO) in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
Authors: O. Mirallas, D.H. Marmolejo Castaneda, D.G. Illescas, D. Gómez-Puerto, R. Berché, A.H. Calvo, M. Vieito Villar, L. Lorini, V. Navarro, J.D. Assaf Pastrana, O. Saavedra, G. Alonso, S. Aguilar Izquierdo, C. Bescós, J. Lorente, J. Giralt, R. Dienstmann, E. Garralda, E. Felip, I. Brana
Journal: Annals of Oncology (2022)
224P Efficacy and safety of tenalisib, a PI3K delta/gamma and SIK3 inhibitor in patients with locally advanced or metastatic breast cancer: Results from a phase II study
Authors: T. Makharadze, I.Z. Kiladze, G. Dzagnidze, N. Semionova-Peskova, L. Katselashvili, N. Vekua, K. Routhu, P. Barde, A. Nair
Journal: Annals of Oncology (2022)
1035P A phase II trial of nivolumab and denosumab association as second-line treatment for stage IV non-small-cell lung cancer (NSCLC) with bone metastases: DENIVOS study (GFPC 06-2017)
Authors: C. Decroisette, I. Monnet, C. Ricordel, A. Demaegdt, L. Falchero, O. Bylicki, M. Geier, G. Justeaux, M. Bernardi, M. Andre, F. Guisier, P. Fournel, S. Vieillot, P.A. Hauss, R. Schott, J. Crequit, J.B. Auliac, C. Chouaid, L. Greillier
Journal: Annals of Oncology (2022)
266P Real-world quality of life (QoL) in patients with HR+/HER2-advanced breast cancer (ABC) treated with palbociclib: Final clinical outcome assessment (COA) analysis from POLARIS
Authors: G. Rocque, J.L. Blum, Y. Ji, T.J. Pluard, J. Migas, S. Lakhanpal, E. Jepsen, E. Gauthier, Y. Wang, M. Montelongo, J.C. Cappelleri, M.S. Karuturi, D. Tripathy
Journal: Annals of Oncology (2022)
1026P Treatment switching adjustment of overall survival in the CheckMate 227 clinical trial of nivolumab plus ipilimumab versus chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer
Authors: M. Reck, T. De, L. Paz-Ares, Y. Yuan, A. Chaudhary, A. Lee, N. Varol, J. Penrod
Journal: Annals of Oncology (2022)
353P Loss of CDX2 and high COX2 (PTGS2) expression in stage IV colorectal cancer
Authors: A.M.D.C. Caldas, W.A. Nunes, R.G. Taboada, M.G. Cesca, J.N. Germano, R.S.P. Riechelmann
Journal: Annals of Oncology (2022)
215MO ICON – a randomized phase IIb study evaluating chemotherapy combined with ipilimumab and nivolumab in metastatic hormone receptor-positive breast cancer
Authors: J.A. Kyte, N.K. Andresen, C. Quaghebeur, B. Gilje, B. Boge, A. Gombos, A. Røssevold, R.M.R. Mathiesen, E. Borgen, R.S. Falk, L. Julsrud, H.G. Russnes, O.C. Lingjærde, B. Naume
Journal: Annals of Oncology (2022)
CN73 Circadian rhythms of cortisol, α-amylase and pro- / anti-inflammatory cytokines of osteosarcoma pediatric patients under chemotherapy
Authors: L.C. Lopes-Júnior, D.S.C. Silveira, L.C. Veronez, J. Santos, G.S. Bisson, R.A.G.D. Lima
Journal: Annals of Oncology (2022)
165P EPclin, OncotypeDx and Prosigna in lobular breast cancer (ILC): Is there an association with Ki67?
Authors: I.I.L. Leao, E. Zamora, R. Cayuela, G. Villacampa Javierre, P. Gomez Pardo, M.A. Arumi de Dios, I. Pimentel, S. Escriva de Romani, C. Ortiz Velez, M. Cruellas Lapena, L. Sanz, M. Borrell Puy, J. De La Torre, M. Espinosa-bravo, T. Gorria, M. Oliveira, C. Saura Manich, V. Peg, M.J. Vidal Losada, M. Bellet Ezquerra
Journal: Annals of Oncology (2022)
CN45 The Gastrointestinal and Lymphoma Unit Advanced Nurse Practitioner role in clinical research at The Royal Marsden Hospital
Authors: L. Hobbis, J. Duncan, F. Kinnaird, C. Fong, S. Li, A. Gordon, I. Chau, N. Starling, S. Rao, D. Watkins, C. Fribbens, D. Cunningham
Journal: Annals of Oncology (2022)
668P Comprehensive analysis of the tumor immune microenvironment (TIM) in advanced adenoid cystic (ACC) and non-adenoid cystic salivary gland cancers (SGC)
Authors: D.T. Rieke, E. Blanc, B. von der Emde, I. Piwonski, F. Klauschen, I. Tinhofer-Keilholz, A. Mock, P. Horak, U. Keller, D. Beule, K. Klinghammer, S. Fröhling, S. Ochsenreither, U. Keilholz
Journal: Annals of Oncology (2022)
904MO Anthracycline-related cardiotoxicity in breast cancer patients carrying mutational signature of homologous recombination deficiency (HRD)
Authors: L. Incorvaia, A. Fiorino, S. Gori, S. Cinieri, G. Curigliano, A. Toss, L. Cortesi, G.R.R. Ricciardi, R. Chiari, M. Peri, C. Brando, T.D. Bazan Russo, V. Gristina, A. Galvano, G. Damerino, I.U. Carreca, G. Novo, G. Badalamenti, V. Bazan, A. Russo
Journal: Annals of Oncology (2022)
573P Role of CA125 in patients included in the DESKTOP III/ENGOT-ov20 trial
Authors: F. Lecuru, J. Sehouli, I.B. Vergote, A. Reuss, J-M. Classe, P. Hillemanns, S. Greggi, M.R. Mirza, P.E. Brachet, P. Follana, N. Raban, A. Hasenburg, R. Zang, K. Lindemann, J-W. Kim, A. Poveda, F. Raspagliesi, C.A. Haslund, A. du Bois, P. Harter
Journal: Annals of Oncology (2022)
1057P Baseline circulating immature neutrophils anticipate hyperprogressive disease (HPD) upon 1st-line PD-1/PD-L1 inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients (pts) and are reduced by platinum-based chemotherapy (PCT) and ICI combinations
Authors: R. Ferrara, G. Lo Russo, C.M. Ciniselli, S. Di Gregorio, G. Calareso, B. Bassani, C. Proto, A. Prelaj, A. De Toma, M. Occhipinti, M. Brambilla, S. Manglaviti, L. Mazzeo, T. Beninato, M. Ganzinelli, F.G.M. De Braud, M.C. Garassino, M.P. Colombo, P. Verderio, S. Sangaletti
Journal: Annals of Oncology (2022)
707TiP Postoperative adjuvant radiochemotherapy (aRCH) with cisplatin versus aRCH with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma: The ADRISK trial
Authors: S. Wiegand, B.F. Tamaskovics, P. Brossart, H. Kaftan, V. Lewitzki, M. Muenter, G. Maschmeyer, N. Rotter, C. Stromberger, M. Beck, T.C. Gauler, U. Schroeder, M. Görner, M. Hautmann, O. Guntinas-Lichius, G. Hapke, S. Dommerich, A. Schmiedeknecht, G. Wichmann, A. Dietz
Journal: Annals of Oncology (2022)
243P Tumor-infiltrating lymphocytes (TILs) in paired samples from patients with phenotypic switch from early luminal-like to metastatic triple-negative breast cancer
Authors: S. Morganti, A. Marra, K. Venetis, E. Sajjadi, L. Ascione, C. Corti, P. Zagami, M. Ivanova, L. Zattoni, G. Curigliano, N. Fusco, C. Criscitiello
Journal: Annals of Oncology (2022)
344P Tumor organoids from multifocal metastatic colorectal cancers for personalized oncology
Authors: K. Kryeziu, K.C.G. Berg, M.Z. Totland, S.H. Moosavi, B. Niederdorfer, S.K. Klokkerud, C.H. Bergsland, T.K.K. Guren, K. Lassen, A. Nesbakken, S. Yaqub, A. Sveen, R.A. Lothe
Journal: Annals of Oncology (2022)
779TiP Commencement of first-in-human phase I/II TCR-T clinical trial targeting shared tumor-specific hotspot mutations in solid tumors
Authors: M.P. Morelli, M.V. Negrao, A. Jazaeri, B. Johnson, P. Kebriaei, D. Deniger, M. Collinson-Pautz, N. Demars, J. Heymach, S. Kopetz
Journal: Annals of Oncology (2022)
885TiP The I-PACE study: Imgatuzumab in PAtients with advanCEd cutaneous squamous cell carcinoma (aCSCC)
Authors: C. Robert, M.R. Migden, F.L. Day, S.E. Bowyer, R.D. Hofheinz, P. Chrom, S. Heeger, D. Rischin
Journal: Annals of Oncology (2022)
839P A retrospective study on the long-term survival and incidence of metachronous malignancies in advanced melanoma patients treated with immune checkpoint blockade (ICB)
Authors: F. Verschaeve, N. Vandelaer, A-S. Vander Mijnsbrugge, J. Tijtgat, J.K. Schwarze, G. Awada, J. Kessels, S. Aspeslagh, W. Cools, A. Rogiers, B. Neyns
Journal: Annals of Oncology (2022)
213MO Primary endpoint analysis of a randomized phase II of darolutamide or capecitabine in patients with triple-negative androgen receptor-positive advanced breast cancer (UCBG3-06 START trial)
Authors: M. Arnedos, A. Goncalves, M. Pulido, F. Lerebours, O. Tredan, F. Dalenc, S. Guiu, D. Mollon Grange, L. Teixeira, C. Levy, B. Verret, H.A.S. Dawood, P. Augereau, L. Deiana, S. Ladoire, E. Carola, M.A. Mouret Reynier, C. Guyonneau, G. MacGrogan, H. Bonnefoi
Journal: Annals of Oncology (2022)
56P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)
Authors: D-Y. Oh, A.R. He, S. Qin, L-T. Chen, T. Okusaka, A. Vogel, J.W. Kim, T. Suksombooncharoen, M.A. Lee, M. Kitano, H.A. Burris, M. Bouattour, S. Tanasanvimon, R.E. Zaucha, A. Avallone, J.E. Cundom, N. Rokutanda, M. Watras, G. Cohen, J.W. Valle
Journal: Annals of Oncology (2022)
501P A prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19
Authors: S. Halabi, B. Luo, H. Dzimitrowicz, C. Hwang, T.M. Wise-Draper, C. Labaki, R.R. McKay, E. Ruiz, C. Rangel-Escareño, D. Farmakiotis, E.A. Griffiths, C.T. Jani, M. Accordino, C. Friese, E. Wulff-Burchfield, M. Puc, P. Yu, U. Topaloglu, S. Mishra, J. Warner
Journal: Annals of Oncology (2022)
281MO Quality of life and neurocognitive function in patients with active brain metastases of HER2-positive breast cancer treated with trastuzumab-deruxtecan: Secondary endpoint analysis of the prospective single-arm phase II TUXEDO-1 trial
Authors: A.M. Starzer, A.S.S. Berghoff, J. Furtner, M. Marhold, E.S. Bergen, S. Roider-Schur, H. Forstner, B. Rottenmanner, K. Dieckmann, Z. Bago-Horvath, G. Widhalm, A. Ilhan-Mutlu, C. Minichsdorfer, T. Fuereder, B. Gruenberger, C. Singer, A. Weltermann, None R. Puhr, M. Preusser, R. Bartsch
Journal: Annals of Oncology (2022)
633P Determining the prognostic value of end of treatment (EOT) 18F-choline positron emission tomography (PET) in patients treated with primary central nervous system lymphoma (PCNSL) who respond to first-line therapy: A single centre retrospective study at the Royal Marsden Hospital (RMH)
Authors: S. Li, B. Sharma, Y. Du, D. El-Sharkawi, S. Iyengar, E. Nicholson, M. Potter, M. Ethell, C. Arias, S. Easdale, E. Alexander, D. Cunningham, I. Chau
Journal: Annals of Oncology (2022)
1051P Radiotherapy (RT) and efficacy of immune checkpoint inhibitors (ICI), chemotherapy (CTx) and chemoimmunotherapy (CIT) in patients with non-small cell lung cancer (NSCLC)
Authors: A. Meisel, M.T. Mark, A. Haider, L. Holer, S. Hayoz, C. Gebhard, S. Bengs, V. Treyer, S.I. Rothschild, M.J. Hochmair, D.R. Gandara, F. Cappuzzo, M. Reck, F. Stenner-Liewen, R.A.F. von Moos
Journal: Annals of Oncology (2022)
303P EO2401 (EO) therapeutic vaccine for patients (pts) with recurrent glioblastoma (GB): Phase I/II ROSALIE study
Authors: D.A. Reardon, A. Idbaih, M. Vieito Villar, G. Tabatabai, A. Stradella, F. Ghiringhelli, M. Burger, M. Gonzalez Rodriguez, A. Hervieu, I. Mildenberger, M. Gil Martín, M. Renovanz, M. Touat, P. Wen, A. Wick, C. Gouttefangeas, A. Maia, C. Bonny, J. Fagerberg, W. Wick
Journal: Annals of Oncology (2022)
84P Pharmacodynamic marker modulation of the selective WEE1 inhibitor Debio 0123 in patient biopsies from phase I clinical trial
Authors: H. Gelderblom, N. Luong, J.A. Gietema, I. Desar, O. Saavedra, M. Jalving, J.R. Kroep, A. Bellon, J. Nowakowska, M. Jonnaert, E. Rodrigo Imedio
Journal: Annals of Oncology (2022)
778TiP A phase I/II trial investigating safety and efficacy of autologous TAC T-cells targeting HER2 in relapsed or refractory solid tumors
Authors: B.L. Schlechter, E.E. Ileana Dumbrava, D. Olson, S. Saibil, B. Pieke, R. Bouvier, K. Moss, N. Turnus, A. Bader, D. Adib
Journal: Annals of Oncology (2022)
897P HORMONET: Phase II trial of tamoxifen for patients (pts) with estrogen/progesterone receptor (ER/PR)-positive neuroendocrine tumors (NET)
Authors: R.S.P. Riechelmann, J. Strosberg, T. Al-Toubah, L. Durant, M.D. Spina Donadio, C.A.L.D. Mello, V.H.F. De Jesus, T.C. Felismino, R.G. Taboada, L. De Brot Andrade, M. Barros
Journal: Annals of Oncology (2022)
1075P Tobacco smoking related mutational signatures (MS) in classifying smoking and non-smoking associated metastatic non-small cell lung cancer (mNSCLC)
Authors: S.M. Ernst, J. Mankor, J. van Riet, J. von der Thüsen, H.J. Dubbink, J.G. Aerts, J. De Langen, E.F. Smit, K. Monkhorst, A-M.C. Dingemans
Journal: Annals of Oncology (2022)
970TiP SKYSCRAPER-05: Phase II study of neoadjuvant atezolizumab (Atezo) + tiragolumab (Tira) with or without platinum-based chemotherapy (CT) in patients (Pts) with locally advanced resectable stage II‒IIIB NSCLC
Authors: H. Pass, A.W. Kim, E. Felip, C.A. Shu, A. Ferris, M. Frueh, B.J. Gitlitz, S. Troutman, H. Petrek, X. Liu, J. Hsu, N. Patil, R.D. Meng
Journal: Annals of Oncology (2022)
457MO A phase I study of ATR inhibitor M1774 in patients with solid tumours (DDRiver Solid Tumours 301): Part A1 results
Authors: T.A. Yap, A.W. Tolcher, R. Plummer, J. Mukker, M. Enderlin, C. Hicking, G. Locatelli, Z. Szucs, I. Gounaris, J.S. de Bono
Journal: Annals of Oncology (2022)
604P T cell density and immune phenotypes at the invasive margin correlate with prognosis in epithelial vulvar cancer
Authors: L. Woelber, N.C. Blessin, A-C. Rolschewski, F. Lutz, T. Mandelkow, C. Yang, E. Bady, V. Reiswich, R. Simon, G. Sauter, S. Mahner, N. De Gregorio, M. Kalder, R. Klapdor, I. Braicu, S. Fuerst, M. Klar, H-G. Strauß, E. Burandt, K. Prieske
Journal: Annals of Oncology (2022)
314O Adjuvant hyperthermic intraperitoneal chemotherapy in locally advanced colon cancer (HIPECT4): A randomized phase III study
Authors: A. Arjona-Sanchez, M.T. Cano-Osuna, A. Gutierrez, J.J. Segura, E. Perez, V. Concepcion, S. Sanchez, A. Garcia, I. Prieto, P. Barrios Sanchez, J. Torres, M. Ramirez, A. Prada, J. Carrasco, M. Artiles, P. Villarejo, G. Ortega, E. Boldo, E. Aranda, S. Rufian
Journal: Annals of Oncology (2022)
396P Impact of depth of response of induction therapy on consecutive maintenance therapy in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212)
Authors: G.M. Sommerhäuser, A. Kurreck, U. Fehrenbach, A. Beck, M. Karthaus, S. Fruehauf, U. Graeven, L. Müller, A.O. Koenig, L. Fischer von Weikersthal, E. Goekkurt, S. Haas, A. Stahler, V. Heinemann, S. Held, A.H.S. Alig, S. Kasper, S. Stintzing, T. Trarbach, D.P. Modest
Journal: Annals of Oncology (2022)
947P Follow-up tests’ profitability in NSCLC: Experience of a tertiary hospital
Authors: V. Calvo de Juan, F. Cano, Y. Garitaonaindía Díaz, A. Collazo Lorduy, F.F. Franco, M. Blanco Clemente, M. Martinez Cutillas, C. Traseira Puchol, R. Aguado, M. Provencio Pulla
Journal: Annals of Oncology (2022)
942P Camrelizumab combined with albumin paclitaxel and platinum in perioperative treatment of resectable squamous cell lung cancer: A single-arm, open-label, phase II clinical trial
Authors: Y. Zhang, S. Liu, L. Yang, Y. Liu, C. Wang, Y. Han, B. Xiao, D. Yan, C. Gong, F. Wang
Journal: Annals of Oncology (2022)
849P Time from primary melanoma to first distant recurrence in relation to survival outcomes in metastatic melanoma
Authors: I.A.J. van Duin, S.G. Elias, F. Van Den Eertwegh, J.W.B. de Groot, W.A.M. Blokx, O.J. van Not, M. Aarts, C.U. Blank, J.B.A.G. Haanen, G. Hospers, D. Piersma, R.S. van Rijn, M. Stevense-den Boer, A.A.M. Van der Veldt, G. Vreugdenhil, M. Wouters, F. Van den Berkmortel, M. Boers-Sonderen, E. Kapiteijn, K.P.M. Suijkerbuijk
Journal: Annals of Oncology (2022)
915P EMLI-ICC: An ensemble machine learning-based proteome and transcriptome integration algorithm for metastasis prediction and risk-stratification in intrahepatic cholangiocarcinoma
Authors: C. Ye, R. Chen, Q. Jiang, W. Wu, F. Yan, Q. Li, X. Shuaishuai, Y. Wang, Y. Jia, X. Zhang, P. Shen, J. Ruan
Journal: Annals of Oncology (2022)
CN14 Cancer prevention awareness among Croatian AYA population
Authors: N. Dodlek, S. Islamčević, J. Miličević, M. Vukoje, A. Sajnic, S. Karabatic, D. Anić, A. Perković, M. Šušnjara, T. Ladenhauser, I. Jelinčić
Journal: Annals of Oncology (2022)
811P Three-years real-world evidence of adjuvant dabrafenib plus trametinib (DT) in patients with resected melanoma in Spain (GEM 1901 - DESCRIBE-AD)
Authors: P. Cerezuela-Fuentes, J. Martín-Liberal, L.A. Fernández-Morales, G. Benítez, J. Medina Martinez, M. Quindós, A. García Castaño, T. Puértolas, R. Vilchez Simo, O. Fernández, M. Majem, L. Bellido Hernández, P. Ayala de Miguel, B. Campos, E. Espinosa, J.A. Macías Cerrolaza, A. Rodríguez-Lescure, L. Espasa Font, G. Belaustegui Ferrández, J.L. Manzano Mozo
Journal: Annals of Oncology (2022)
600P Ethnic and socio-economic status in ovarian cancer patients recruited to clinical trials
Authors: K.R. Palmer, K.H. El-Shakankery, J. Kefas, K. Gao, S. Crusz, M. Flynn, L. Jonathan, M. Lockley, M. McCormack, N. Macdonald, S. Nicum, M-J. Devlin, R. Miller
Journal: Annals of Oncology (2022)
840P Electronic patient-reported outcomes (ePROs) of adults with BRAF V600–mutant stage III-IV melanoma treated with dabrafenib + trametinib (D + T) collected using the Kaiku Health digital patient (pt) monitoring platform
Authors: J. Lijnsvelt, A. Addeo, M.G. Vitale, P. Mohr, P. Queirolo, J. Ekström, J. Vainio, V.V. Kataja, F. Calado, A. Fagan, M.R. Lau, T. Romero Salas, H. Thole-Glettig, C.U. Blank, P.A. Ascierto
Journal: Annals of Oncology (2022)
703TiP A randomised, double-blind, placebo-controlled phase II study of setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (rmSCCHN)
Authors: A. Rullan, D.R. Adkins, P. Bossi, E.E.W. Cohen, A. Daste, K.J. Harrington, C. Le Tourneau, L.F. Licitra, N. Little, T. Morris, C.H.H. Ottensmeier, M. Reinwald, T. Rutkowski
Journal: Annals of Oncology (2022)
750P Phase I study of TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa (BA) in patients (pts) with metastatic/locally advanced solid unresectable tumours
Authors: L.L. Siu, M.A. Mckean, A.W. Tolcher, A. Victor, T. Kitzing, V. Pierre, S. Gleicher, D.G. Holland, E. Richter, A. Naing
Journal: Annals of Oncology (2022)
401P PROMETCO study: Metastatic colorectal cancer treatment patterns of the first 531 enrolled patients
Authors: J-B. Bachet, C. Pinto, G.M. Bodoky, F.E. Marti, A. Mitroshkin, E. Choucair, M. Fazilleau, A. Sullivan, R. Garcia-Carbonero, M. Koopman
Journal: Annals of Oncology (2022)
752P Novel CEAxCD3 (NILK-2301) and CEAxCD28 (NILK-3301) κλ bispecific antibodies for next generation immunotherapy of CEA-expressing cancer
Authors: A. Seckinger, S. Majocchi, V. Moine, L. Nouveau, B. Daubeuf, V. Buatois, F. Gueneau, U. Ravn, K. Masternak, Y. Poitevin, G. Magistrelli, P. Malinge, L. Shang, N. Fischer, K. Strein, W.G. Ferlin, D. Hose
Journal: Annals of Oncology (2022)
1050P Association of ctDNA quantification with prognosis and early prediction of response to first-line osimertinib in NSCLC patients
Authors: M.G. Denis, G. Herbreteau, S. Charpentier, A. Vallée, J. Cadranel, C. Audigier Valette, P. Tomasini, P. Masson, E. Pons-Tostivint, R. Gervais, N. Girard, A. Cortot, O. Molinier, I. Monnet, M. Marcq, T. Urban, D. Moro-Sibilot, H. Lena, C. Sagan, J. Bennouna
Journal: Annals of Oncology (2022)
414P Long-term follow-up of the randomized trial of the conventional technique versus the no-touch isolation technique for primary tumor resection in patients with colon cancer ( JCOG1006)
Authors: Y. Takii, J. Mizusawa, Y. Kanemitsu, K. Komori, M. Shiozawa, M. Ohue, S. Ikeda, N. Takiguchi, T. Kobatake, H. Ike, T. Sato, N. Tomita, M. Ota, E. Sunami, T. Hamaguchi, D. Shida, H. Katayama, Y. Shimada, H. Fukuda
Journal: Annals of Oncology (2022)
503P The IMPRESS-Norway trial: Improving public cancer care by implementing precision cancer medicine in Norway
Authors: A. Helland, K. Tasken, H.E.G. Russnes, L. Fagereng, E.S. Blix, S. Brabrand, T. Donnem, Å. Flobak, B.T. Gjertsen, A. Haug, R. Hovland, G. Inpred, P.E. Lonning, P. Niehusmann, K. Puco, E.S. Samdal, S. Smeland
Journal: Annals of Oncology (2022)
788O Association of pre-treatment ctDNA with disease recurrence and clinical and translational factors in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy (CheckMate 915)
Authors: G.V. Long, K. Desai, T. Tang, J.S. Weber, S. Dolfi, C. Ritchings, S-P. Huang, M. Bolisetty, M. Sausen, M. Del Vecchio, J. Larkin, J. Baden, D. Balli, H. Chang, J. Loffredo, N. Zhang, M. Wind-Rotolo, D. Tenney
Journal: Annals of Oncology (2022)
460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers
Authors: K. Jhaveri, H. Han, E. Dotan, D-Y. Oh, C. Ferrario, A. Tolcher, K-W. Lee, C-Y. Liao, Y-K. Kang, Y.H. Kim, E. Hamilton, A. Spira, N. Patel, C. Karapetis, S.Y. Rha, L. Boyken, J. Woolery, P. Bedard
Journal: Annals of Oncology (2022)